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An International Expert Committee with
members appointed by the American Diabe-
tes Association, the European Association for
the Study of Diabetes, and the International
DiabetesFederationwasconvenedin2008to
consider the current and future means of di-
agnosing diabetes in nonpregnant individu-
als. The report of the International Expert
Committee represents the consensus view of
its members and not necessarily the view of
the organizations that appointed them. The
International Expert Committee hopes that
itsreportwillserveasastimulustotheinter-
nationalcommunityandprofessionalorgani-
zations to consider the use of the A1C assay
for the diagnosis of diabetes.
D
iabetes is a disease characterized
by abnormal metabolism, most
notably hyperglycemia, and an
associated heightened risk for relatively
speciﬁc long-term complications af-
fecting the eyes, kidney, and nervous
system. Although diabetes also substan-
tially increases the risk for cardiovas-
cular disease, cardiovascular disease is
not speciﬁc to diabetes and the risk for
cardiovascular disease has not been in-
corporated into previous deﬁnitions or
classiﬁcations of diabetes or of subdia-
betic hyperglycemia.
BACKGROUND
Diagnosing diabetes based on the
distribution of glucose levels
Historically, the measurement of glucose
has been the means of diagnosing diabe-
tes. Type 1 diabetes has a sufﬁciently
characteristic clinical onset, with rela-
tivelyacute,extremeelevationsinglucose
concentrations accompanied by symp-
toms, such that speciﬁc blood glucose cut
points are not required for diagnosis in
most clinical settings. On the other hand,
type 2 diabetes has a more gradual onset,
with slowly rising glucose levels over
time, and its diagnosis has required spec-
iﬁed glucose values to distinguish patho-
logic glucose concentrations from the
distribution of glucose concentrations in
the nondiabetic population. Virtually ev-
eryschemefortheclassiﬁcationanddiag-
nosis of diabetes in modern times has
relied on the measurement of plasma (or
blood or serum) glucose concentrations
in timed samples, such as fasting glucose;
incasualsamplesindependentofprandial
status; or after a standardized metabolic
stress test, such as the 75-g oral glucose
tolerance test (OGTT).
Early attempts to standardize the def-
inition of diabetes relied on the OGTT,
buttheperformanceandinterpretationof
thetestwereinconsistentandthenumber
of subjects studied to deﬁne abnormal
values was very small (1–6). Studies in
thehigh-riskPimaIndianpopulationthat
demonstrated a bimodal distribution of
glucose levels following the OGTT (7,8)
helpedestablishthe2-hvalueasthediag-
nostic value of choice, even though most
populations had a unimodal distribution
of glucose levels (9). Of note, a bimodal
distribution was also seen in the fasting
glucose samples in the Pimas and other
high-risk populations (10,11). However,
a discrete fasting plasma glucose (FPG) or
2-hplasmaglucose(2HPG)levelthatsep-
aratedthebimodaldistributionsinthePi-
mas was difﬁcult to identify, with
potential FPG and 2HPG cut points rang-
ing from 120 to 160 mg/dl (6.7–8.9
mmol/l) and from 200 to 250 mg/dl
(11.1–13.9 mmol/l), respectively.
In 1979, the National Diabetes Data
Group (NDDG) provided the diagnostic
criteria that would serve as the blueprint
for nearly two decades (12). The NDDG
relied on distributions of glucose levels,
rather than on the relationship of glucose
levels with complications, to diagnose di-
abetes despite emerging evidence that the
microvascular complications of diabetes
were associated with a higher range of
fasting and OGTT glucose values (11,13–
15).Thediagnosticglucosevalueschosen
were based on their association with de-
compensation to “overt” or symptomatic
diabetes.
When selecting the threshold glucose
values, the NDDG acknowledged that
“thereisnocleardivisionbetweendiabet-
ics and nondiabetics in the FPG concen-
trationortheirresponsetoanoralglucose
load,”andconsequently,“anarbitraryde-
cision has been made as to what level jus-
tiﬁes the diagnosis of diabetes.” The
diagnosis of diabetes was made when 1)
classic symptoms were present; 2) the ve-
nous FPG was 140 mg/dl (7.8 mmol/
l); or 3) after a 75-g glucose load, the
venous 2HPG and levels from an earlier
sample before 2 h were 200 mg/dl
(11.1 mmol/l). An intermediate group
wasclassiﬁedashaving“impairedglucose
tolerance” (IGT) with FPG 140 mg/dl
(7.8 mmol/l) and a 2HPG value between
140 and 200 mg/dl (7.8–11.1 mmol/l).
IGT was identiﬁed on the basis of its rel-
atively higher risk of progression to dia-
betes compared with that of “normal”
glucose tolerance, low frequency of “dia-
betic symptoms,” high probability of re-
verting to normal glucose tolerance or
continuing to have IGT, and rarity of
“clinically signiﬁcant” microvascular dis-
ease. The NDDG recommendations were
also promulgated by the contemporane-
ous report of the World Health Organiza-
tion (WHO) (16).
Diagnosing diabetes based on the
relationship between glucose levels
and long-term complications
In 1997, the Expert Committee on the
Diagnosis and Classiﬁcation of Diabetes
Mellitus (17) reexamined the basis for di-
agnosing diabetes. This committee made
two seminal contributions: First, they re-
focused attention on the relationship be-
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long-term complications as the basis for
the diagnosis of diabetes. Second, they
summarized data negating the wide-
spread hypothesis that the 2HPG was the
gold-standard test for diagnosing diabe-
tes. The committee examined data from
three cross-sectional epidemiologi-
cal studies that included an Egyptian
population (n  1,018), Pima Indians
(n  960), and the U.S. National Health
and Nutrition Examination Survey
(NHANES) population (n  2,821). Each
assessedretinopathywithfundusphotog-
raphy or direct ophthalmoscopy and
measured glycemia as FPG, 2HPG, and
A1C. These studies demonstrated glyce-
mic levels below which there was little
prevalent retinopathy and above which
theprevalenceofretinopathyincreasedin
an apparently linear fashion (Fig. 1).
When the prevalence of retinopathy was
expressed by deciles of glycemia for each
ofthethreemeasures,thedecilesatwhich
retinopathy began to increase were the
same for each measure within each pop-
ulation. Moreover, the glycemic values
above which retinopathy increased were
similar among the populations. These
data showed a clear relationship between
glycemia and the risk for retinopathy that
would supplant the previous notion of
riskforprogressiontoovert,symptomatic
diabetes as the basis for diagnosing
diabetes.
In comparing the relationship be-
tweenFPGand2HPGvaluesandretinop-
athy, it was apparent that the previous
FPG cut point of 140 mg/dl (7.8
mmol/l) was substantially above the glu-
cose level at which the prevalence of ret-
inopathy began to increase. As a result,
the committee recommended that the
FPG cut point be lowered to 126 mg/dl
(7.0 mmol/l) so that this cut point would
represent a degree of hyperglycemia that
was “similar” to the 2HPG value and di-
agnosis with either measure would result
in a similar prevalence of diabetes in the
population. The 1997 committee report
acknowledged that even at the lower FPG
cut point, the FPG and OGTT (2HPG)
were not perfectly concordant. An indi-
vidual could have diabetes using one test
but not the other. This discrepancy has
been conﬁrmed in numerous subsequent
reportsandmaybedue,inpart,tothefact
that although both tests are measures of
glycemia, they reﬂect different physiolog-
icalmeasuresofacuteglucosemetabolism
(18). The debate regarding the relative
rolesofFPGand2HPGinthediagnosisof
diabetes in the nonpregnant adult has
continued (19–21).
The 1997 report also recommended
that the FPG level, rather than the 2HPG,
be the preferred test to diagnose diabetes
because it was more convenient for pa-
tients and less costly and time consuming
and the repeat-test reproducibility was
superior (17). In addition, the committee
introduced the term “impaired fasting
glucose” (IFG) to differentiate the meta-
bolic state between a normal state (FPG
110 mg/dl or 6.1 mmol/l) and diabe-
tes (126 mg/dl or 7.0 mmol/l) when
the FPG test was used. If an OGTT was
performed, the intermediate glycemic
state continued to be called IGT, with the
2HPG (between 140 and 200 mg/dl [7.8
and 11.1 mmol/l]) the same as that as in
the NDDG report. A WHO consultation
(22) adopted most of the above recom-
mendations except they concluded that,
Figure 1—Prevalence of retinopathy by deciles of the distribution of FPG, 2HPG, and A1C in
PimaIndians(A),Egyptians(B),and40-to74-year-oldparticipantsinNHANESIII(C).Adapted
with permission from ref. 17.
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should be given an OGTT to exclude the
presenceofdiabetesthatwouldotherwise
be missed and that the OGTT should re-
main the “gold standard.” A 2003 fol-
low-up report from the expert committee
reﬁned the fasting glucose value range for
IFGfrom110but126mg/dlto100
but 126 mg/dl (6.1 but 7.0 mmol/l
to 5.6 but 7.0 mmol/l) to make it
more comparable with the IGT value
(21). The WHO did not change its previ-
ous recommendations (23).
CAN THE A1C TEST BE USED
TO DIAGNOSE DIABETES?—I f
chronic hyperglycemia sufﬁcient to cause
diabetes-speciﬁc complications is the
hallmark of diabetes, common sense
would dictate that laboratory measures
thatcapturelong-termglycemicexposure
should provide a better marker for the
presence and severity of the disease than
single measures of glucose concentration.
Observational studies that have assessed
glycemia with measures that capture
longer-term exposure (i.e., A1C) or with
single or longitudinal measurements of
glucose levels have consistently demon-
strated a strong correlation between reti-
nopathy and A1C (24–26) but a less
consistent relationship with fasting glu-
cose levels (27). In one study that mea-
sured both FPG and A1C, there was a
stronger correlation between A1C and
retinopathy than between fasting glucose
levels and retinopathy (25). The correla-
tion between A1C levels and complica-
tionshasalsobeenshowninthesettingof
controlledclinicaltrialsintype1(28)and
type 2 (29) diabetes, and these ﬁndings
have been used to establish the widely ac-
cepted A1C treatment goals for diabetes
care (30).
All of these observations suggest that
a reliable measure of chronic glycemic
levels such as A1C, which captures the
degree of glucose exposure over time
(31,32) and which is related more inti-
mately to the risk of complications than
singleorepisodicmeasuresofglucoselev-
els, may serve as a better biochemical
marker of diabetes and should be consid-
ered a diagnostic tool. Although the 1997
expert committee report considered this
option, it recommended against using
A1C values for diagnosis in part because
of the lack of assay standardization (17).
The 2003 follow-up report noted that,
while the National Glycohemoglobin
Standardization Program (33) had suc-
ceeded in standardizing the vast majority
of assays used in the U.S., the use of A1C
for diagnosis still had “disadvantages,”
anditreafﬁrmedthepreviousrecommen-
dation that A1C not be used to diagnose
diabetes (21).
An updated examination of the labo-
ratory measurements of glucose and A1C
by the current International Expert Com-
mittee indicates that with advances in in-
strumentation and standardization, the
accuracy and precision of A1C assays at
least match those of glucose assays. The
measurementofglucoseitselfislessaccu-
rate and precise than most clinicians real-
ize (34). A recent analysis of the per-
formanceofavarietyofclinicallaboratory
instruments and methods that measure
glucose revealed that 41% of instruments
have a signiﬁcant bias from the reference
method that would result in potential
misclassiﬁcation of 12% of patients
(35). There are also potential preana-
lytic errors owing to sample handling and
the well-recognized lability of glucose in
the collection tube at room temperature
(36,37). Even when whole blood samples
are collected in sodium ﬂuoride to inhibit
in vitro glycolysis, storage at room tem-
perature for as little as 1 to 4 h before
analysismayresultindecreasesinglucose
levels by 3–10 mg/dl in nondiabetic indi-
viduals (36–39).
By contrast, A1C values are relatively
stable after collection (40), and the recent
introduction of a new reference method
to calibrate all A1C assay instruments
should further improve A1C assay stan-
dardizationinmostoftheworld(41–43).
In addition, between- and within-subject
coefﬁcients of variation have been shown
to be substantially lower for A1C than for
glucose measurements (44). The variabil-
ity of A1C values is also considerably less
than that of FPG levels, with day-to-day
within-person variance of 2% for A1C
but 12–15% for FPG (45–47). The con-
venience for the patient and ease of sam-
ple collection for A1C testing (which can
be obtained at any time, requires no pa-
tient preparation, and is relatively stable
atroomtemperature)comparedwiththat
of FPG testing (which requires a timed
sample after at least an 8-h fast and which
is unstable at room temperature) support
using the A1C assay to diagnose diabetes.
Insummary,comparedwiththemea-
surement of glucose, the A1C assay is at
least as good at deﬁning the level of hy-
perglycemia at which retinopathy preva-
lence increases; has appreciably superior
technical attributes, including less pre-
analytic instability and less biologic vari-
ability; and is more clinically convenient.
A1Cisamorestablebiologicalindexthan
FPG, as would be expected with a mea-
sure of chronic glycemia levels compared
with glucose concentrations that are
known to ﬂuctuate within and between
days (Table 1).
WHAT IS THE MOST
APPROPRIATE A1C CUT
POINT FOR THE DIAGNOSIS
OF DIABETES? — As shown in the
1997 committee report, the prevalence of
retinopathy increases substantially at
A1C values starting between 6.0 and
7.0% (17) (Fig. 1). A recent analysis de-
rivedfromDETECT-2(48)andincluding
the 3 that were included in the 1997
report examined the association between
A1C and retinopathy, objectively
assessed and graded by fundus photogra-
phy (S. Colagiuri, personal communica-
tion). This analysis included 28,000
subjects from nine countries and showed
that the glycemic level at which the prev-
alence of “any” retinopathy begins to rise
abovebackgroundlevels(anyretinopathy
includesminorchangesthatcanbedueto
other conditions, such as hypertension),
and for the more diabetes-speciﬁc “mod-
erate” retinopathy, was 6.5% when the
data were examined in 0.5% increments
(Fig. 2). Among the 20,000 subjects
who had A1C values 6.5%, “moderate”
retinopathy was virtually nonexistent.
The receiver operating characteristic
curve analysis of the same data indicated
that the optimal cut point for detecting at
least moderate retinopathy was an A1C of
6.5%.
In summary, the large volume of data
from diverse populations has now estab-
lished an A1C level associated with an in-
crease in the prevalence of moderate
Table 1—Advantages of A1C testing com-
pared with FPG or 2HPG for the diagnosis of
diabetes
● Standardized and aligned to the DCCT/
UKPDS; measurement of glucose is less
well standardized
● Better index of overall glycemic exposure
and risk for long-term complications
● Substantially less biologic variability
● Substantially less preanalytic instability
● No need for fasting or timed samples
● Relatively unaffected by acute (e.g., stress
or illness related) perturbations in glucose
levels
● Currently used to guide management and
adjust therapy
International Expert Committee
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tion for assigning an A1C cut point of
6.5% for the diagnosis of diabetes. A
recently published population-based
study of 3,190 adults of Malay ethnicity
independently concluded that A1C levels
“in the range 6.6 to 7% were optimal for
detecting microvascular complications”
(26).
Any suggestion that the relationship
between chronic glycemic levels and the
long-term complications of diabetes may
be better expressed as a continuum,
rather than as a strictly dichotomous re-
lationship, is belied by the retinopathy
ﬁndings presented herein. There is a low
prevalence of “any” retinopathy at A1C
levels 6.5% that may reﬂect a contin-
uum of risk; alternatively, retinopathy re-
lated to conditions other than diabetes
(e.g., hypertension) or inaccurate assess-
ment of long-term glycemic levels with a
single A1C measurement may contribute
to this observation. However, the sub-
stantialincreaseintheprevalenceofmod-
erate retinopathy at A1C levels 6.5%
supportsathresholdlevelofglycemiathat
results in retinopathy most characteristic
of diabetes.
This cut point should not be con-
strued as an absolute dividing line be-
tween normal glycemia and diabetes;
however, the A1C level of 6.5% is sufﬁ-
ciently sensitive and speciﬁc to identify
individuals who are at risk for developing
retinopathy and who should be diag-
nosedasdiabetic.TheA1Clevelisatleast
as predictive as the current FPG and
2HPG values. In selecting a diagnostic
A1C level 6.5%, the International Ex-
pert Committee balanced the stigma and
costs of mistakenly identifying individu-
alsasdiabeticagainsttheminimalclinical
consequencesofdelayingthediagnosisin
someone with an A1C level 6.5%. The
committee agreed to emphasize speciﬁc-
ity rather than sensitivity. This decision
was aided by the parallel decision to rec-
ommend effective prevention strategies
for the highest at-risk group with an A1C
between 6.0 and 6.5%. (See below.)
LIMITATIONS OF A1C AS
THE RECOMMENDED
MEANS OF DIAGNOSING
DIABETES— The A1C assay is the
testofchoiceforthechronicmanagement
of diabetes and is now being recom-
mended for its diagnosis; however, there
are parts of the world where the costs of
providing the assay preclude its routine
use. In such circumstances, clinicians
shouldcontinuetousethepreviouslyrec-
ommended approaches to diagnose dia-
betes based on glucose measurements.
The International Expert Committee en-
courages clinicians worldwide to move as
quickly as possible to A1C testing using
standardized methods and instrumenta-
tion. However, the decision to change to
A1C assays as the means of diagnosing
diabetesshouldtakeintoaccounttheper-
formanceoflocalA1Cassaysandthelocal
prevalence of conditions that may inter-
fere with the assay. (See below.)
Althoughthediscussionaboveargues
for using the A1C assay for the diagnosis
of diabetes in nonpregnant individuals,
there are patient conditions that either
will require a speciﬁc A1C assay method
or will preclude A1C testing. First, some
hemoglobin traits, such as HbS, HbC,
HbF, and HbE, interfere with some A1C
assay methods (49). Currently, many as-
say methods can correct for the presence
of the most common hemoglobin traits
(www.ngsp.org), and afﬁnity assays that
are unaffected by hemoglobin traits may
be used (49). Second, any condition that
changes red cell turnover, such as hemo-
lytic anemia, chronic malaria, major
blood loss, or blood transfusions, will
lead to spurious A1C results. Clinicians
mustbeawareoftheseconditions,partic-
ularly in populations in which they are
more prevalent. As in the setting where
A1C assays are unavailable, the tradi-
tional diagnostic tests (e.g., FPG, 2HPG)
must be used in individuals in whom in-
terpreting the A1C is problematic. Third,
A1C levels appear to increase with age
(50), but the extent of the change,
whether it relates to factors other than
glucose metabolism, and the effect of the
age-related increases on the development
of complications are not sufﬁciently clear
to adopt age-speciﬁc values in a diagnos-
tic scheme. Similarly, racial disparities in
A1C, based on putative differences in the
relationship between glucose levels and
A1C, have been suggested (51); however,
here too, their etiology and signiﬁcance
are unclear, and it is premature to estab-
lish race-speciﬁc diagnostic values. Fi-
nally, there are rare clinical settings, such
as rapidly evolving type 1 diabetes, where
the A1C level will not have had time to
“catch up” with the acute elevations in
glucoselevels;however,intheseveryrare
cases, diabetes should be diagnosable
withtypicalsymptomsandcasualglucose
levels 200 mg/dl (11.1 mmol/l) despite
a nondiagnostic A1C level.
Notwithstanding the above limita-
tionsofA1Ctesting,theassayhasnumer-
ous important advantages compared with
the currently used laboratory measure-
ments of glucose (Table 1). The preva-
lence of diabetes in some populations
Figure 2—Prevalence of retinopathy by 0.5% intervals and severity of retinopathy in participants aged 20–79 years. NPDR, nonproliferative
diabetic retinopathy. Adapted with permission from (S. Colagiuri, personal communication).
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based on A1C compared with diagnosis
with glucose measurements, and one
methodmayidentifydifferentindividuals
thantheother.Becausethemeasurements
of glucose levels and A1C reﬂect different
aspects of glucose metabolism, this is to
be expected. However, establishing iden-
ticalprevalencesshouldnotbethegoalin
deﬁning a new means of diagnosing dia-
betes. The ultimate goal is to identify in-
dividuals at risk for diabetes compli-
cations so that they can be treated. The
A1C diagnostic level of 6.5% accom-
plishes this goal.
CAN A1C MEASUREMENTS
DEFINE A SPECIFIC
SUBDIABETIC “HIGH-
RISK” STATE?— The 2003 Inter-
national Expert Committee report re-
duced the lower bound of IFG from 110
mg/dl (6.1 mmol/l) to 100 mg/dl (5.6
mmol/l) on the grounds that the lower
level optimized the sensitivity and speci-
ﬁcity for predicting future diabetes and
also increased the proportion of those
with IGT who could be identiﬁed with an
FPG test (21). While previous studies
have shown a powerful effect of IFG
and/or IGT on the subsequent develop-
ment of diabetes diagnosed with glucose
values (52–54), recent reports have dem-
onstrated a graded risk of diabetes devel-
opment at glycemic levels well within
what was previously considered “nor-
mal,” i.e., FPG 100 mg/dl (5.6 mmol/l)
and A1C 6.0% (55,56). In addition,
metabolic derangements related to diabe-
tes have been documented at similarly
low glycemic levels, increasing in severity
with higher glucose values within the
nondiabetic range (57,58).
As with measures of glucose, a con-
tinuum of risk for the development of di-
abetes based on A1C levels has been
demonstrated(59–61).Thus,whilethere
appears to be an approximate glycemic
threshold above which the risk for reti-
nopathy escalates, there does not appear
to be a speciﬁc level at which risk for di-
abetesclearlybegins.Acontinuumofrisk
for the development of diabetes across a
wide range of subdiabetic A1C levels may
make the classiﬁcation of individuals into
categories similar to IFG and IGT equally
problematic for A1C, as it implies that we
actually know where risk begins or be-
comes clinically important. The contin-
uum of risk in the subdiabetic glycemic
rangearguesfortheeliminationofdichot-
omoussubdiabeticclassiﬁcations,suchas
“pre-diabetes,” IFG, and IGT. However,
as A1C levels approach the diagnostic
level for diabetes, the risk of developing
diabetes becomes greatest (59,60,62).
SHOULD A1C TESTING BE
USED TO IDENTIFY
INDIVIDUALS AT HIGH RISK
FOR DIABETES? — The screening
tests to identify individuals at elevated
risk for diabetes are the same as the diag-
nostic tests; therefore, the technical ad-
vantages of A1C testing compared with
glucose testing apply to the detection of
individuals at high risk as they do to the
diagnosis of diabetes. Therapeutic deci-
sions should be based on how close A1C
levels are to the diagnosis of diabetes. In
theabsenceofaspeciﬁcidentiﬁablelower
threshold deﬁning when prevention ef-
forts should be implemented, and with
potentially limited resources taken into
consideration, individuals whose A1C val-
ues are close to the 6.5% A1C threshold of
diabetes (i.e., 6.0%) should receive de-
monstrably effective interventions (63,64).
By identifying this very high-risk subdia-
betic group, the International Expert
Committee is implying not that popula-
tions at lower A1C levels are not at risk
but, rather, that they are at lower risk. All
individuals at risk for diabetes should re-
ceive counseling to maintain normal
weight, lose weight if necessary, and be-
come more physically active.
Other risk factors for diabetes devel-
opment in addition to A1C have been
identiﬁed, including elevated levels of
triglycerides, blood pressure, BMI, and
family history of diabetes (59,60), and
these should be taken into account in de-
termining when to initiate interventions
in individuals with A1C 6.0%. The use
of well-validated risk assessment tools
may be valuable in that regard. At the
population level, the A1C value at which
prevention services are provided will de-
pend on the resources available, the size
ofthetargetpopulation,andthenatureof
the intervention.
WHAT ARE THE PRACTICAL
ISSUES RELATED TO A1C
TESTING?— A1C tests to diagnose
diabetes should be performed using clin-
ical laboratory equipment. Point-of-care
instruments have not yet been shown to
be sufﬁciently accurate or precise for di-
agnosing diabetes. Although this Interna-
tional Expert Committee has concluded
that the attributes of the A1C assay with
regard to diagnosing diabetes and detect-
ingindividualsathighrisksupportitsuse
over the FPG or 2HPG tests, the superior-
ity of A1C testing does not invalidate the
diagnostic criteria based on glucose test-
ing. In circumstances when A1C testing
cannot be performed, the diagnostic glu-
cose tests are acceptable alternatives.
Whichever of the three different tests
now available to diagnose diabetes (A1C,
FPG, and 2HPG) is used, both initial and
conﬁrmatorytestingshouldbeperformed
with the same test. As the three tests are
not completely concordant, using differ-
ent tests could easily lead to confusion.
Theonlyexceptiontotheneedtoconﬁrm
the diagnosis of diabetes with the same
test would be the presence of clinical
symptoms characteristic of diabetes and
glucoselevels200mg/dl(11.1mmol/
l). Conﬁrmatory testing is also not requir-
ed to establish risk status in individuals
identiﬁed as in the highest-risk group for
diabetes (A1C of 6.0 to 6.5%).
Most cases of type 1 diabetes, partic-
ularly in children and adolescents, are di-
agnosed by the classical symptoms of
polyuria, polydipsia, polyphagia, unex-
plained weight loss, and a casual glucose
200 mg/dl. If diabetes is suspected in
theabsenceofthoseconditions,A1Ctest-
ing is warranted.
RECOMMENDATIONS AND
CONCLUSIONS — Basedontheabove
discussion, the International Expert Com-
mittee has concluded that the best current
evidence supports the following recom-
mendations, summarized in Table 2.
For the diagnosis of diabetes
● There is no single assay related to hy-
perglycemia that can be considered
the gold standard, as it relates to the
riskformicrovascularormacrovascular
complications.
● A measure that captures chronic glu-
coseexposureismorelikelytobeinfor-
mative regarding the presence of
diabetes than is a single measure of
glucose.
● The A1C assay provides a reliable mea-
sure of chronic glycemia and correlates
well with the risk of long-term diabetes
complications.
● TheA1Cassay(standardizedandaligned
withtheDiabetesControlandComplica-
tions Trial/UK Prospective Diabetes
Study assay) has several technical, in-
cluding preanalytic and analytic, advan-
International Expert Committee
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measurements of glucose.
● For the reasons above, the A1C assay
may be a better means of diagnosing
diabetes than measures of glucose
levels.
● The diagnosis of diabetes is made if the
A1C level is 6.5%. Diagnosis should
beconﬁrmedwitharepeatA1Ctestun-
less clinical symptoms and glucose lev-
els 200 mg/dl (11.1 mmol/l) are
present.
● If A1C testing is not possible owing to
patient factors that preclude its inter-
pretation (e.g., hemoglobinopathy or
abnormal erythrocyte turnover) or to
unavailability of the assay, previously
recommended diagnostic measures
(e.g., FPG and 2HPG) and criteria
should be used. Mixing different meth-
ods to diagnose diabetes should be
avoided.
● Inchildrenandadolescents,A1Ctest-
ing is indicated when diabetes is sus-
pected in the absence of the classi-
cal symptoms or a plasma glucose
concentration 200 mg/dl (11.1
mmol/l).
● The diagnosis of diabetes during preg-
nancy, when changes in red cell turn-
over make the A1C assay problema-
tic, will continue to require glucose
measurements.
For the identiﬁcation of individuals
at high risk for diabetes
● IndividualswithanA1Clevel6%but
6.5% are likely at the highest risk for
progression to diabetes, but this range
should not be considered an absolute
threshold at which preventative mea-
sures are initiated.
● The classiﬁcation of subdiabetic hyper-
glycemia as pre-diabetes is problematic
because it suggests that all individuals
so classiﬁed will develop diabetes and
that individuals who do not meet these
glycemia-driven criteria (regardless of
other risk factor values) are unlikely to
develop diabetes—neither of which is
thecase.Moreover,thecategoricalclas-
siﬁcation of individuals as high risk
(e.g., IFG or IGT) or low risk, based on
any measure of glycemia, is less than
idealbecausetheriskforprogressionto
diabetes appears to be a continuum.
The glucose-related terms describing
subdiabetic hyperglycemia will be
phased out of use as clinical diagnostic
states as A1C measurements replace
glucosemeasurementsforthediagnosis
of diabetes.
● When assessing risk, implementing
prevention strategies, or initiating a
population-based prevention program,
other diabetes risk factors should be
taken into account. In addition, the
A1C level at which to begin preventa-
tive measures should reﬂect the re-
sources available, the size of the
population affected, and the antici-
pated degree of success of the interven-
tion. Further analyses of cost-beneﬁt
should guide the selection of high-risk
groups targeted for intervention within
speciﬁc populations.
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